Browsing Tag
pembrolizumab
32 posts
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Citius Oncology (CTOR) balances LYMPHIR launch momentum with cash runway pressure after Q2 loss
Citius Oncology has LYMPHIR revenue, but cash runway only reaches November 2026. Investors now face launch proof versus dilution risk.
TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data
TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience.
Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment?
Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact.
NHS adopts 60-second Keytruda jab as Merck races to convert 14,000 UK patients before biosimilars hit
Merck's Keytruda patent expires in 2028. The NHS just gave it a 60-second injection to lock in patients before biosimilars arrive. The race is on.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
How Brazilian drugmaker Blau Farmacêutica quietly built a pembrolizumab biosimilar that could challenge Big Pharma
Blau Farmacêutica completes Brazil’s first full pembrolizumab biosimilar. Find out how this could reshape global immunotherapy access and biosimilar strategy.